Evidence map›Paper›PMID 29246518›Full record

ArticleGenomics, proteomics & bioinformatics2017

Interactome Analysis of Microtubule-targeting Agents Reveals Cytotoxicity Bases in Normal Cells.

Andrés Julián Gutiérrez-Escobar, Gina Méndez-Callejas

Open access · goldAbstract read
In one paragraph

Article in Genomics, proteomics & bioinformatics, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.2field-weighted citation impact, top 42% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 4 citations in OpenAlex.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors at 1 institution in 1 country.

Andrés Julián Gutiérrez-EscobarGrupo de Investigaciones Biomédicas y Genética Aplicada - GIBGA, Universidad de Ciencias Aplicadas y Ambientales U.D.C.A., Bogotá 111166, Colombia. Electronic address: andresjulian1981@gmail.com.
Gina Méndez-CallejasGrupo de Investigaciones Biomédicas y Genética Aplicada - GIBGA, Universidad de Ciencias Aplicadas y Ambientales U.D.C.A., Bogotá 111166, Colombia.
University of Applied and Environmental Sciences · CO

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Cancer causes millions of deaths annually and microtubule-targeting agents (MTAs) are the most commonly-used anti-cancer drugs. However, the high toxicity of MTAs on normal cells raises great concern. Due to the non-selectivity of MTA targets, we analyzed the interaction network in a non-cancerous human cell. Subnetworks of fourteen MTAs were reconstructed and the merged network was compared against a randomized network to evaluate the functional richness. We found that 71.4% of the MTA interactome nodes are shared, which affects cellular processes such as apoptosis, cell differentiation, cell cycle control, stress response, and regulation of energy metabolism. Additionally, possible secondary targets were identified as client proteins of interphase microtubules. MTAs affect apoptosis signaling pathways by interacting with client proteins of interphase microtubules, suggesting that their primary targets are non-tumor cells. The paclitaxel and doxorubicin networks share essential topological axes, suggesting synergistic effects. This may explain the exacerbated toxicity observed when paclitaxel and doxorubicin are used in combination for cancer treatment.

Indexed as

ApoptosisAntineoplastic AgentsCell DifferentiationCell Line, TumorDNA DamageDoxorubicinHumansMicrotubulesProteomeProteomicsAntineoplastic AgentsDoxorubicinProteomeApoptosisCancer biologyCancer treatmentInteractome analysisMicrotubule-targeting agent

Identifiers

PMID29246518
PMCPMC5828656
OpenAlexW2771991153

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.